Does development of a cough while on Angiotensin-Converting Enzyme (ACE) inhibitor therapy necessitate discontinuation of the medication?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 8, 2025View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

From the Guidelines

If someone develops a cough while taking an ACE inhibitor, the medication should be stopped if the cough is severe, disruptive to sleep, or significantly affects quality of life, and an alternative such as an angiotensin II receptor blocker (ARB) should be considered. In patients who develop a cough while taking an ACE inhibitor, the decision to stop the medication depends on the severity of the cough and its impact on the patient's quality of life 1. ACE inhibitor-induced cough is a common side effect that occurs in about 5-35% of patients and is typically dry, persistent, and often worse at night.

Key Considerations

  • For patients with a mild cough that doesn't significantly impact their daily activities, continuing the medication while monitoring symptoms may be reasonable.
  • However, if the cough is severe, disruptive to sleep, or significantly affects quality of life, switching to an alternative medication is recommended.
  • The most appropriate alternative is usually an angiotensin II receptor blocker (ARB) such as losartan, valsartan, or irbesartan, which provide similar cardiovascular benefits without causing cough, as supported by the ACCP guidelines 1.

Management Approach

  • The cough occurs because ACE inhibitors increase bradykinin levels in the lungs, which stimulates nerve endings and triggers the cough reflex.
  • Importantly, the cough is not harmful but can take up to 4 weeks to resolve after stopping the ACE inhibitor.
  • Patients should not stop their medication without consulting their healthcare provider first to ensure proper blood pressure management is maintained.
  • In patients in whom persistent or intolerable ACE inhibitor-induced cough occurs, therapy should be switched, when indicated, to an ARB, with which the incidence of associated cough appears to be similar to that for the control drug, or to an appropriate agent of another drug class, as recommended by the ACCP guidelines 1.

From the FDA Drug Label

Presumably due to the inhibition of the degradation of endogenous bradykinin, persistent nonproductive cough has been reported with all ACE inhibitors, always resolving after discontinuation of therapy. ACE inhibitor-induced cough should be considered in the differential diagnosis of cough Presumably caused by inhibition of the degradation of endogenous bradykinin, persistent nonproductive cough has been reported with all ACE inhibitors, always resolving after discontinuation of therapy. Consider the possibility of angiotensin converting enzyme inhibitor induced-cough in the differential diagnosis of cough Cough Persistent dry cough (with an incidence of a few percent) has been associated with ACE-inhibitor use and in practice can be a cause of discontinuation of ACE-inhibitor therapy

Cough associated with ACE inhibitors is a known side effect.

  • The incidence of cough is not well defined but is reported to occur in a few percent of patients.
  • Discontinuation of ACE inhibitor therapy may be necessary if the cough is persistent and bothersome.
  • Alternative antihypertensive therapy, such as an angiotensin receptor blocker (ARB), may be considered in patients who develop a cough while taking an ACE inhibitor 2, 3, 4.

From the Research

ACE Inhibitor-Induced Cough Management

  • The development of a cough in patients taking ACE inhibitors is a common adverse effect, with an incidence rate ranging from 10% to 20% of patients 5, 6, 7.
  • The mechanisms underlying ACE inhibitor-induced cough are likely linked to the suppression of kininase II activity, leading to an accumulation of kinins, substance P, and prostaglandins 7.
  • Strategies for managing ACE inhibitor-induced cough include:
    • Temporarily discontinuing the ACE inhibitor and reintroducing it after the cough has resolved 5.
    • Adding calcium channel blockers to the ACE inhibitor regimen 5, 6.
    • Switching to alternative drugs, such as angiotensin receptor blockers, if the cough is intolerable and other causes have been excluded 5, 8.
  • In some cases, the cough may resolve naturally or disappear while the patient continues to take the medication 6.
  • The use of pharmacologic treatments, such as cromolyn, baclofen, theophylline, sulindac, and local anesthetics, may also be considered to manage the cough 9.

Incidence and Characteristics of ACE Inhibitor-Induced Cough

  • The incidence of cough varies among individual ACE inhibitors, with perindopril having the lowest incidence 5.
  • Cough is more frequently observed in women than in men 6.
  • The onset of cough can occur at any time, even months or a year after starting ACE inhibitor therapy 7.
  • Concomitant use of calcium antagonists or diuretics may reduce the frequency of cough 6.
  • Taking the medication at bedtime may also reduce the frequency of cough 6.

Comparison with Other Antihypertensives

  • ACE inhibitors have a higher incidence of cough compared to placebo, angiotensin receptor blockers, and calcium channel blockers 8.
  • The risk of cough is similar among all ACE inhibitors, with moexipril having the highest risk and spirapril having the lowest risk 8.

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.